Phase 2/3 Trial of Oral Troriluzole in Easing Alzheimer’s Dementia Fully Enrolled

Phase 2/3 Trial of Oral Troriluzole in Easing Alzheimer’s Dementia Fully Enrolled
Biohaven announced that its Phase 2/3 study of the investigational oral therapy troriluzole (BHV-4157) in treating symptoms of mild to moderate Alzheimer's disease (AD) has fully enrolled more than 700 patients. The T2 Protect AD trial will assess if troriluzole use can protect against or slow memory and cognitive skill loss due to Alzheimer's, and potentially improve these abilities in patients. A preliminary analysis of troriluzole's effects on cognition and brain volume loss, a sign of AD progression, is expected by late December. "We are extremely grateful to all the trial participants and their families, as well as our trial sites, for helping us achieve this milestone," said Irfan Qureshi, MD, Biohaven's vice president of Neurology, said in a press release. "We believe that troriluzole is a promising potential therapy for people suffering from Alzheimer's disease and look forward to the study results, including the interim analysis by the end of this year," he added. Troriluzole, also known as BHV-4157, is a new compound precursor of riluzole — an approved medication for amyotrophic lateral sclerosis (ALS) — designed to regulate glutamate activity, one of the most abundant and important signaling molecules in the brain. Glutamate works by exciting nerve cells, and under normal conditions, it plays an important role in learning and memory. Abnormal sensitivity or high levels of glutamate, however, can lead to the overexcitation that can damage and kill nerve cells. Troriluzole acts by lowering glutamate-mediated stimulation. It does so by increasing the reabsorption of glutamate, clearing it from synapses, the point of communication between nerve cells. Preclinical studies in animal models and post-mortem human brain samples suggest that
Subscribe or to access all post and page content.